STAA
What one share of STAAR Surgical holds
Ophthalmic Goods
STAAR generates worldwide revenue almost exclusively from sales of our Implantable Collamer Lenses, or “ICLs.” Our ICLs are made from Collamer, which is a proprietary collagen copolymer material created and
STAAR Surgical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-03; the balance sheet is as of 2026-07-03.
| Sales | $6.72 |
|---|---|
| Profit | $0.08 |
| Capex (buildings and equipment) | $0.07 |
| Free cash flow | −$0.13 |
| Cash and investments | $2.96 |
| Book value | $7.29 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.04 | −$0.30 | $0.08 | −$0.05 | — | $0.93 |
| 2017 | $2.21 | −$0.05 | $0.03 | $0.04 | — | $1.04 |
| 2018 | $2.74 | $0.11 | $0.05 | $0.23 | — | $3.00 |
| 2019 | $3.20 | $0.30 | $0.22 | $0.33 | — | $3.57 |
| 2020 | $3.41 | $0.12 | $0.18 | $0.26 | — | $4.24 |
| 2021 | $4.66 | $0.56 | $0.28 | $0.61 | — | $5.48 |
| 2022 | $4.85 | $0.80 | $0.37 | $0.36 | — | $6.97 |
| 2023 | $6.52 | $0.43 | $0.37 | −$0.07 | — | $7.90 |
| 2024 | $6.39 | −$0.41 | $0.48 | −$0.16 | — | $8.06 |
| 2025 | $4.83 | −$1.62 | $0.12 | −$0.81 | — | $6.97 |